Phenethylamine

Phenethylamine, or β-Phenylethylamine
(2-Phenylethylamine), is an alkaloid and monoamine.
Phenethylamine also has a constitutional isomer α-Phenylethylamine
(1-Phenylethylamine), which has two stereoisomers:
(R)-(+)-1-phenylethylamine and (S)-(-)-1-phenylethylamine.
In the human brain, 2-phenethylamine is believed to function as a neuromodulator or
neurotransmitter (trace amine). Phenethylamine is a natural compound
biosynthesized from the amino acid phenylalanine by enzymatic
decarboxylation. It is also found in many foods such as chocolate,
especially after microbial fermentation.
It has been suggested that phenethylamine from food may have
psychoactive effects in sufficient quantities. However, it is quickly
metabolized by the enzyme MAO-B,
preventing significant concentrations from reaching the brain. In oral
doses of 500-4,000 mg or 10-60 mg with deprenyl however it bypasses
MAO-B Breakdown and reaches the brain where it has Psychedelic effects.
Substituted phenethylamines are a broad and
diverse class of compounds that include neurotransmitters, hormones,
stimulants, hallucinogens, entactogens, anorectics, bronchodilators,
and antidepressants.
BANNER
HERE
Phenethylamine
EXTENSIONS AND
COMMENTARY:
Here is the chemical that is central to this entire book. This is the
structural point of departure for every compound that is discussed
here. It is the RPS in PIHKAL. It is without activity in man! Certainly
not for the lack of trying, as some of the dosage trials that are
tucked away in the literature (as abstracted in the "Qualitative
Comments" given above) are pretty heavy duty. Actually, I truly doubt
that all of the experimenters used exactly that phrase, "No effects,"
but it is patently obvious that no effects were found. It happened to
be the phrase I had used in my own notes.
This, the
simplest of all phenethylamines, has always been the darling of the
psychopharmacologists in that it is structurally clean, it is naturally
present in various human fluids and tissues, and because of its close
chemical relationship to amphetamine and to the neurotransmitters.
These facts continuously encourage theories that involve PEA in mental
illness. Its levels in urine may be decreased in people diagnosed as
being depressed. Its levels may be increased in people diagnosed as
being paranoid schizophrenics. Maybe it is also increased in people
under extreme stress. The human trials were initially an attempt to
provoke some psychological change, and indeed some clinicians have
reported intense headaches generated in depressives following PEA
administration. But then, others have seen nothing. The studies evolved
into searches for metabolic difference that might be of some diagnostic
value. And even here, the jury is still out.
Phenethylamine
is found throughout nature, in both plants and animals. It is the end
product of phenylalanine in the putrefaction of tissue. One of its most
popularized occurrences has been as a major component of chocolate, and
it has hit the Sunday Supplements as the love-sickness chemical. Those
falling out of love are compulsive chocolate eaters, trying to
replenish and repair the body's loss of this compound--or so the myth
goes. But this amine is voraciously metabolized to the apparently
inactive compound phenylacetic acid, and to some tyramine as well. Both
of these products are also normal components in the body. And, as a wry
side-comment, phenylacetic acid is a major precursor in the illicit
synthesis of amphetamine and methamphetamine.
Phenethylamine
is intrinsically a stimulant, although it doesn't last long enough to
express this property. In other words, it is rapidly and completely
destroyed in the human body. It is only when a number of substituent
groups are placed here or there on the molecule that this metabolic
fate is avoided and pharmacological activity becomes apparent.
To a large
measure, this book has emphasized the "phenyl" end of the
phenethylamine molecule, and the "what," the "where," and the "how
many" of the substituent groups involved. There is a broad variety of
chemical groups that can be attached to the benzene ring, at one or
more of the five available positions, and in an unending number of
combinations. And, in any given molecule, the greater the number of
substituents on the benzene ring, the greater the likelihood that there
will be psychedelic action rather that stimulant action.
But what
can be said about the "ethylamine" end of the phenethylamine molecule?
This is the veritable backbone that holds everything together, and
simple changes here can produce new prototypes that can serve as
starting points for the substituent game on the benzene ring. Thus,
just as there is a "family" of compounds based on the foundation of
phenethylamine itself, there is an equally varied and rich "families"
of other compounds that might be based on some phenethylamine with a
small modification to its backbone.
So, for
the moment, leave the aromatic ring alone, and let us explore simple
changes in the ethylamine chain itself. And the simplest structural
unit of change is a single carbon atom, called the methyl group. Where
can it be placed?
The adding
of a methyl group adjacent to the amine produces phenylisopropylamine,
or amphetamine. This has been exploited already as one of the richest
families of psychedelic drugs; and over half of the recipes in Book II
are specifically for amphetamine analogues with various substituents on
the aromatic ring. The further methylation of amphetamine with yet
another methyl group, this time on the nitrogen atom, yields
methamphetamine. Here the track record with various substituents on the
aromatic ring is not nearly as good. Many have been explored and, with
one exception, the quality and potency of human activity is down. But
the one exception, the N-methyl analogue of MDA, proved to be the most
remarkable MDMA.
The
placement of the methyl group between the two carbons (so to speak)
produces a cyclopropyl system. The simplest example is
2-phenylcyclopropylamine, a drug with the generic name of
tranylcypromine and the trade name Parnate. It is a mono-amine oxidase
inhibitor and has been marketed as an antidepressant, but the compound
is also a mild stimulant causing insomnia, restlessness and
photophobia. Substitutions on the benzene ring of this system have not
been too promising. The DOM analogue,
2,5-dimethoxy-4-methyltranylcypromine is active in man, and is
discussed in its own recipe under DMCPA. The inactive mescaline
analogue TMT is also mentioned there.
The
dropping of one carbon from the phenethylamine chain gives a benzyl
amine, basically an inactive nucleus. Two families deserve mention,
however. The phencylidine area, phenylcyclohexylpiperidine or PCP, is
represented by a number of benzyl amines. Ketamine is also a benzyl
amine. These are all analgesics and anesthetics with central properties
far removed from the stimulant area, and are not really part of this
book. There is a benzyl amine that is a pure stimulant, which has been
closely compared to amphetamine in its action This is benzylpiperazine,
a base that is active in the 20 to 100 milligram range, but which has
an acceptability similar to amphetamine. If this is a valid stimulant,
I think that much magic might be found in and around compounds such as
(1) the MDMA analogue, N-(3,4-methylenedioxybenzyl)piperazine (or its
N-methyl-counterpart N-(3,4-methylenedioxybenzyl)-N'-methylpiperazine)
or (2) the DOM analogue, 2,5-dimethoxy-4-methylbenzylpiperazine. The
benzyl amine that results by the relocation of the amine group of MDA
from the beta-carbon atom to the alpha-carbon atom is known, and is
active. It, and its N-methyl homologue, are described and discussed in
the commentary under MDA. Dropping another carbon atom gives a yet
shorter chain (no carbons at all!) and this is to be found in the
phenylpiperazine analogue 3-trifluoromethylphenylpiperazine. I have
been told that this base is an active hallucinogen as the
dihydrobromide salt at 50 milligrams sublingually, or at 15 milligrams
intravenously in man. The corresponding 3-chloro analogue at 20 to 40
milligrams orally in man or at 8 milligrams intravenously, led to panic
attacks in some 10% of the experimental subjects, but not to any
observed psychedelic or stimulant responses.
What
happens if you extend the chain to a third carbon? The parent system is
called the phenyl-(n)-propylamine, and the parent chain structure,
either as the primary amine or as its alpha-methyl counterpart,
represents compounds that are inactive as stimulants. The DOM-analogues
have been made and are, at least in the rabbit rectal hyperthermia
assay, uninteresting. A commercially available fine chemical known as
piperonylacetone has been offered as either of two materials. One,
correctly called 3,4-methylenedioxyphenylacetone or
3,4-methylenedioxybenzyl methyl ketone, gives rise upon reductive
amination to MDA (using ammonia) or MDMA (using methylamine). This is
an aromatic compound with a three-carbon side-chain and the
amine-nitrogen on the beta-carbon. The other so-called piperonylacetone
is really 3,4-methylenedioxybenzylacetone, an aromatic compound with a
four-carbon side-chain. It produces, on reductive amination with
ammonia or methylamine, the corresponding
alpha-methyl-(n)-propylamines, with a four-carbon side-chain and the
amine-nitrogen on the gamma-carbon. They are completely unexplored in
man and so it is not known whether they are or are not psychedelic. As
possible mis-synthesized products, they may appear quite
unintentionally and must be evaluated as totally new materials. The
gamma-amine analogue of MDA, a methylenedioxy substituted three carbon
side-chain with the amine-nitrogen on the gamma carbon, has indeed been
made and evaluated, and is discussed under MDA. The extension of the
chain of mescaline to three atoms, by the inclusion of an oxygen atom,
has produced two compounds that have also been assayed. They are
mentioned in the recipe for mescaline.
The chain
that reaches out to the amine group can be tied back in again to the
ring, with a second chain. There are 2-aminobenzoindanes which are
phenethylamines with a one-carbon link tying the alpha-position of the
chain back to the aromatic ring. And there are 2-aminotetralines which
are phenethylamines which have a two-carbon link tying the
alpha-position of the chain back to the aromatic ring. Both
unsubstituted ring systems are known and both are fair stimulants. Both
systems have been modified with the DOM substituent patterns (called
DOM-AI and DOM-AT respectively), but neither of these has been tried in
man. And the analogues with the MDA substitution pattern are discussed
elsewhere in this book.
And there
is one more obvious remaining methylation pattern. What about
phenethylamine or amphetamine compounds with two methyl groups on the
nitrogen? The parent amphetamine example, N,N-dimethylamphetamine, has
received much notoriety lately in that it has become a scheduled drug
in the United States. Ephedrine is a major precursor in the illicit
synthesis of methamphetamine, and with the increased law-enforcement
attention being paid to this process, there has been increasing
promotion of the unrestricted homologue, N-methylephedrine, to the
methamphetamine chemist. This starting material gives rise to
N,N-dimethylamphetamine which is a material of dubious stimulant
properties. A number of N,N-dimethylamphetamine derivatives, with
"psychedelic" ring substituents, have been explored as iodinated
brain-flow indicators, and they are explicitly named within the
appropriate recipes. But none of them have shown any psychedelic
action.
This is as
good a place as any to discuss two or three simple compounds,
phenethylamines, with only one substituent on the benzene ring. The
2-carbon analog of 4-MA, is 4-methoxyphenethylamine, or MPEA. This is a
kissing cousin to DMPEA, of such fame in the search for a urine factor
that could be related to schizophrenia. And the end results of the
search for this compound in the urine of mentally ill patients are as
controversial as they were for DMPEA. There has been no confirmed
relationship to the diagnosis. And efforts to see if it is centrally
active were failures--at dosages of up to 400 milligrams in man, there
was no activity. The 4-chloro-analogue is 4-chlorophenethylamine
(4-Cl-PEA) and it has actually been pushed up to even higher levels (to
500 milligrams dosage, orally) and it is also without activity. A
passing bit of charming trivia. A positional isomer of MPEA is
3-methoxyphenethylamine (3-MPEA) and, although there are no reported
human trials with this, it has been graced with an Edgewood Arsenal
code number, vis., EA-1302.
Substitution table Phenethylamine
| Tyramine |
|
|
|
|
OH |
|
|
4-hydroxy-phenethylamine |
| Dopamine |
|
|
|
OH |
OH |
|
|
3,4-dihydroxy-phenethylamine |
| Epinephrine (Adrenaline) |
|
OH |
|
OH |
OH |
|
CH3 |
β,3,4-trihydroxy-N-methylphenethylamine |
| Norepinephrine
(Noradrenaline) |
|
OH |
|
OH |
OH |
|
|
β,3,4-trihydroxyphenethylamine |
| Phenylephrine |
|
OH |
|
OH |
|
|
CH3 |
β,3-dihydroxy-N-methylphenethylamine |
| 6-Hydroxydopamine |
|
|
OH |
|
OH |
OH |
|
2,4,5-trihydroxyphenethylamine |
| Salbutamol |
|
OH |
|
|
OH |
CH2OH |
C(CH3)3 |
β,4-dihydroxy-3-hydroxymethyl-N-tert-butyl-phenethylamine |
| Beta-methyl-phenethylamine |
|
CH3 |
|
|
|
|
|
β-methylphenethylamine |
| Amphetamine |
CH3 |
|
|
|
|
|
|
α-methylphenethylamine |
| Methamphetamine |
CH3 |
|
|
|
|
|
CH3 |
N-methylamphetamine |
| Methylphenidate |
|
|
|
|
|
|
|
N,α-butylene-β-methoxycarbonylphenethylamine |
Ephedrine,
pseudoephedrine |
CH3 |
OH |
|
|
|
|
CH3 |
N-methyl-β-hydroxyamphetamine |
| Acetylamphetamine |
CH3 |
|
|
COCH3 |
|
|
|
α-methyl-3-acetylphenethylamine |
| Cathine |
CH3 |
OH |
|
|
|
|
|
β-hydroxy-amphetamine |
| Cathinone |
CH3 |
=O |
|
|
|
|
|
β-ketoamphetamine |
| Methcathinone |
CH3 |
=O |
|
|
|
|
CH3 |
N-methyl-β-ketoamphetamine |
| Bupropion |
CH3 |
=O |
|
Cl |
|
|
C(CH3)3 |
3-chloro-N-tert-butyl-β-ketoamphetamine |
| Fenfluramine |
CH3 |
|
|
CF3 |
|
|
CH2CH3 |
3-trifluoromethyl-N-ethyl-amphetamine |
| Phentermine |
2CH3 |
|
|
|
|
|
|
α,α-dimethylphenethylamine |
| Mescaline |
|
|
|
OCH3 |
OCH3 |
OCH3 |
|
3,4,5-trimethoxyphenethylamine |
| MDA |
CH3 |
|
|
-O-CH2-O- |
|
|
3,4-methylenedioxyamphetamine |
| MDMA |
CH3 |
|
|
-O-CH2-O- |
|
CH3 |
3,4-methylenedioxy-N-methylamphetamine |
| MDMC |
CH3 |
=O |
|
-O-CH2-O- |
|
CH3 |
3,4-methylenedioxy-N-methyl-β-ketoamphetamine |
| DOM |
CH3 |
|
OCH3 |
|
CH3 |
OCH3 |
|
2,5-dimethoxy-4-methylamphetamine |
| DOB |
CH3 |
|
OCH3 |
|
Br |
OCH3 |
|
2,5-dimethoxy-4-bromoamphetamine |
| DON |
CH3 |
|
OCH3 |
|
NO2 |
OCH3 |
|
2,5-dimethoxy-4-nitroamphetamine |
| 2C-B |
|
|
OCH3 |
|
Br |
OCH3 |
|
2,5-dimethoxy-4-bromophenethylamine |
| 2C-C |
|
|
OCH3 |
|
Cl |
OCH3 |
|
2,5-dimethoxy-4-chlorophenethylamine |
| DOI |
CH3 |
|
OCH3 |
|
I |
OCH3 |
|
2,5-dimethoxy-4-iodoamphetamine |
| 2C-I |
|
|
OCH3 |
|
I |
OCH3 |
|
2,5-dimethoxy-4-iodophenethylamine |
| 2C-D |
|
|
OCH3 |
|
CH3 |
OCH3 |
|
2,5-dimethoxy-4-methylphenethylamine |
| 2C-E |
|
|
OCH3 |
|
CH2-CH3 |
OCH3 |
|
2,5-dimethoxy-4-ethylphenethylamine |
| 2C-F |
|
|
OCH3 |
|
F |
OCH3 |
|
2,5-dimethoxy-4-fluorophenethylamine |
| 2C-N |
|
|
OCH3 |
|
NO2 |
OCH3 |
|
2,5-dimethoxy-4-nitrophenethylamine |
| 2C-T-2 |
|
|
OCH3 |
|
S-CH2CH3 |
OCH3 |
|
2,5-dimethoxy-4-ethylthio-phenethylamine |
| 2C-T-4 |
|
|
OCH3 |
|
S-CH(CH3)2 |
OCH3 |
|
2,5-dimethoxy-4-isopropylthio-phenethylamine |
| 2C-T-7 |
|
|
OCH3 |
|
S-CH2CH2CH3 |
OCH3 |
|
2,5-dimethoxy-4-propylthio-phenethylamine |
| 2C-T-8 |
|
|
OCH3 |
|
S-CH2-C3H5 |
OCH3 |
|
2,5-dimethoxy-4-cyclopropylmethylthio-phenethylamine |
| 2C-T-9 |
|
|
OCH3 |
|
S-C(CH3)3 |
OCH3 |
|
2,5-dimethoxy-4-tert-butylthio-phenethylamine |
| 2C-T-21 |
|
|
OCH3 |
|
S-CH2-CH2-F |
OCH3 |
|
2,5-dimethoxy-4-(2-fluoroethylthio)-phenethylamine |